This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire

PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions

Company to host Corporate Update call on Wednesday, December 10, 2025

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter and provided a corporate update.

The third quarter of 2025 marked a pivotal period for Spectral, highlighted by the announcement of topline results from the T

See Full Page